Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension

Kidney International

Volumn 72, Issue 6, 2007, Pages 683-689

  Capdevila, J H ^a   Falck, J R ^b   Imig, J D ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Blood pressure; Epithelial sodium channel; Hemodynamics and vascular regulation; Hypertension

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID; CYTOCHROME P450; EPOXYICOSATRIENOIC ACID; UNSPECIFIC MONOOXYGENASE;

BLOOD PRESSURE REGULATION; ENZYME ACTIVITY; ENZYME MECHANISM; GENETIC VARIABILITY; HUMAN; HYPERTENSION; ION TRANSPORT; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC CIRCULATION; TRANSCRIPTION REGULATION;

ANIMALS; ARACHIDONIC ACID; BLOOD PRESSURE; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; MICE; MICE, MUTANT STRAINS;

EID: 34548480936     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002394     Document Type: Review

References (62)

1. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signaling pathways and environmental carcinogenesis. Nat Rev Cancer 2006; 6: 947-960.
2. Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 2006; 8: 101-111, and cited references.
3. Capdevila JH, Falck JR. The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochem Biophys Res Commun 2001; 285: 571-576, and cited references.
4. McGiff JC, Quilley J. 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure. Curr Opin Nephrol Hypertens 2001; 10: 231-237, and cited references.
5. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82: 131-185, and cited references.
6. Capdevila JH, Falck JR. Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. Prostaglandins Other Lipid Mediat 2002; 68-69: 325-344, and cited references.
7. Spector AA, Fang X, Snyder GD et al. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 2004; 43: 55-90, and cited references.
8. Imig JD. Eicosanoids and renal vascular function in diseases. Clin Sci (London) 2006; 111: 21-34, and cited references.
9. Michaelis UR, Fleming I. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol Ther 2006; 111: 584-595, and cited references.
10. Nebert DW, Nelson DR, Coon MJ et al. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 1991; 10: 1-14.
11. Cheng PY, Morgan ET. Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2001; 2: 165-183, and cited references.
12. Johnson EF, Hsu MH, Savas U et al. Regulation of P450 4A expression by peroxisome proliferator activated receptors. Toxicology 2002; 181-182: 203-206, and cited references.
13. Waxman DJ, O'Connor C. Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol 2006; 20: 2613-2629, and cited references.
14. Zeldin DC, Foley J, Ma J et al. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Mol Pharmacol 1996; 50: 1111-1117.
15. Lasker JM, Chen WB, Wolf I et al. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem 2000; 275: 4118-4126.
16. Carroll MA, Schwartzman M, Sacerdoti D et al. Novel arachidonate metabolites. Am J Med Sci 1988; 295: 268-274.
17. Wang MH, Guan H, Nguyen X et al. Contribution of cytochrome P-450 4A1 and 4A2 to vascular 20-hydroxyeicosatetraenoic acid synthesis in rat kidneys. Am J Physiol 1999; 276: F246-F253.
18. Sarkis A, Lopez B, Roman RJ. Role of 20-Hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr Op Nephrol Hypertens 2004; 13: 205-214, and cited references.
19. Sankaralingam S, Desai KM, Glaeser H et al. Inability to upregulate cytochrome P450 4A and 2C causes salt sensitive hypertension in young Sprague-Dawley rats. Am J Hypertens 2006; 19: 1174-1180.
20. Ito O, Omata K, Ito S et al. Effects of converting enzyme inhibitors on renal P-450 metabolism of arachidonic acid. Am J Physiol 2001; 280: 822-830.
21. Kaergel E, Muller DN, Honeck H et al. P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. Hypertension 2002; 40: 273-279.
22. Kohagura K, Arims S, Endo Y et al. Involvement of cytochrome P450 metabolites in the vascular actions of angiotensin II on the afferent arterioles. Hypertens Res 2001; 24: 551-557.
23. Alonson-Galicia M, Maier KG, Green AS et al. Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor action of angiotensin II. Am J Physiol 2002; 283: R60-R68.
24. Muller DN, Theuer J, Shagdarsuren E et al. A peroxisomal proliferator-activated receptor-α activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Am J Pathol 2004; 164: 521-532.
25. Jacobson HR, Corona S, Capdevila JH et al. Effects of epoxyeicosatrienoic acids on ion transport in the rabbit cortical collecting tubule. In: Braquet PJC, Frolich S, Nicosia, Garay R (eds). Prostaglandins and Membrane Ion Transport. Raven Press: New York, 1984, p 311.
26. Holla VR, Makita K, Zaphiropoulus PG et al. The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J Clin Invest 1999; 104: 751-760.
27. Makita K, Takahashi K, Karara A et al. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J Clin Invest 1994; 94: 2414-2420.
28. Imig JD, Falck JR, Wei S et al. Epoxygenase metabolites contribute to the nitric oxide-independent afferent arteriolar vasodilation to bradykinin. J Vasc Res 2001; 38: 247-255.
29. Campbell WB, Gebremedhin D, Pratt PF et al. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996; 78: 415-423.
30. Campbell WB, Falck JR. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension 2007; 49: 590-596.
31. Gonzalez FJ, Kimura S. Study of P450 function using gene knockout and transgenic mice. Arch Biochem Biophys 2003; 409: 153-158, and cited references.
32. Vallon V. In vivo studies of the genetically modified mouse kidney. Nephrol Physiol 2003; 94: 1-5, and cited references.
33. D'Orleans-Juste P, Honore JC, Carrier E et al. Cardiovascular diseases: new insights from knockout mice. Curr Opin Pharmacol 2003; 3: 181-185, and cited references.
34. Heng YM, Kuo CS, Jones PS et al. A novel murine gene, Cyp4a14, is part of a cluster of Cyp4a and 4b, but not Cyp4F genes in mouse and humans. Biochem J 1997; 325: 741-749.
35. Holla VR, Adas F, Imig JD et al. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci USA 2001; 98: 5211-5216.
36. Nakagawa K, Holla VR, Wei Y et al. Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J Clin Invest 2006; 116: 1696-1702.
37. Muller DN, Schmidt C, Barbosa-Sicard E et al. Mouse Cyp4a isoforms: gender and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J 2007; 403: 109-118.
38. Nakagawa K, Marji JS, Schwartzman ML et al. Androgen-mediated induction of the kidney arachidonate hydroxylases is associated with the development of hypertension. Am J Physiol 2003; 284: E1055-R1063.
39. Chen YF, Meng QC. Sexual dimorphism of blood pressure in spontaneously hypertensive rats is androgen dependent. Life Sci 1991; 48: 85-96, and cited references.
40. Reckelhoff JF, Zhang H, Srivastava K et al. Gender differences in hypertensive rats: role of androgens and androgen receptor. Hypertension 1999; 34: 920-923, and cited references.
41. Garbers DL, Dubois SK. The molecular basis of hypertension. Annu Rev Biochem 1999; 68: 127-155, and cited references.
42. Reckelhoff JF, Granger JP. Role of androgen in mediating hypertension and renal injury. Clin Exp Pharmacol Physiol 1999; 26: 127-131, and cited references.
43. Chen YF. Sexual dimorphism of hypertension. Curr Opin Nephrol Hypertens 1996; 5: 181-185, and cited references.
44. Cowley AW, Roman RJ. The role of the kidney in hypertension. J Am Med Assoc 1996; 275: 1581-1589.
45. Inscho EW, Carmines PK, Cook AK et al. Afferent arteriole responsiveness to altered perfusion pressure in renal hypertension. Hypertension 1990; 15: 748-752.
46. Bouriquet N, Casellas D. Chronic L-NAME hypertension in rats and autoregulation of juxtamedullary preglomerular vessels. Am J Physiol 1995; 269: F190-F197.
47. Inscho EW, Cook AK, Murynowski JB et al. Elevated arterial pressure impairs autoregulation independently of AT1 receptor activation. J Hypertension 2004; 22: 811-818.
48. Wei Y, Lin DH, Kemp R et al. Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase dependent pathways. J Gen Physiol 2004; 124: 719-727.
49. Rossier BC, Pradervand S, Schild L et al. Epithelial sodium channel and the control of sodium balance: interactions between genetic and environmental factors. Ann Rev Physiol 2002; 64: 877-897, and cited references.
50. Snyder PM. The epithelial Na+ channel: cell surface insertion and retrieval in Na+ homeostasis and hypertension. Endocrine Revs 2002; 23: 258-275, and cited references.
51. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104: 545-556, and cited references.
52. Shaughnessy KM, Karet FE. Salt handling and hypertension. J Clin Invest 2004; 113: 1075-1081, and cited references.
53. DeLozier TC, Tsao CC, Coulter SJ et al. CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products. J Pharmacol Exp Ther 2004; 310: 845-854.
54. Savas U, Griffin KJ, Johnson EF. Molecular mechanisms of cytochrome P450 induction by xenobiotics: an expanded role for nuclear hormone receptors. Mol Pharmacol 1999; 56: 651-857, and cited references.
55. Schild L, Schneeberger E, Gautschi I et al. Identification of amino acid residues in the alpha, beta, and gamma subunits of the epithelial sodium channel (ENaC) involved in amiloride block and ion permeation. J Gen Physiol 1997; 109: 15-26.
56. Bellamine A, Wang Y, Waterman MR et al. Characterization of the CYP4A11 gene, a second CYP4A gene in humans. Arch Biochem Biophys 2003; 409: 221-227.
57. Zeldin DC, DuBois RN, Falck JR et al. Molecular cloning and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biophys Biochem 1995; 322: 76-86.
58. Gainer JV, Bellamine A, Dawson EP et al. A functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005; 111: 63-69.
59. Mayer B, Lieb WQ, Gotz A et al. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg Echocardiographic Substudy. Hpertension 2005; 46: 766-771.
60. Laffer CL, Laniado-Schwartzman M, Wang MH et al. Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic acid in human salt-sensitive versus salt-resistant hypertension. Circulation 2003; 107: 574-578.
61. Chen JK, Falck JR, Reddy KM et al. epoxyeicosatrienoic acids and their sulfonimide derivatives stimulate tyrosine phosphorylation and induce mitogenesis in renal epithelial cells. J Biol Chem 1998; 273: 29254-29261.
62. Chen JK, Wang DW, Falck JR et al. Transfection of an active cytochrome P450 arachidonic acid epoxygenase indicated that 14,15- epoxyeicosatrienoic acid functions as an intracellular second messenger in response to epidermal growth factor. J Biol Chem 1999; 274: 4764-4769.